down arrow

Allarity Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0167443029
USD
1.16
-0.04 (-3.33%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.091.18

52 Week

0.612.35
Valuation
Technical
Day's Volume

CASH

171.51 k

Shareholding (Jun 2025)

FII

1.18%

Held by 3 FIIs

DII

97.68%

Held by 1 DIIs

Promoter

0.00%

How big is Allarity Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Allarity Therapeutics, Inc. has a market capitalization of 12.46 million, with net sales of 0.00 million and a net profit of -23.40 million over the last four quarters. The company reported shareholder's funds of 11.81 million and total assets of 22.65 million as of Dec 24.

Market Cap: As of Jun 18, Allarity Therapeutics, Inc. has a market capitalization of 12.46 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Allarity Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -23.40 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company had shareholder's funds amounting to 11.81 million and total assets of 22.65 million.

Read More

What does Allarity Therapeutics, Inc. do?

22-Jun-2025

Allarity Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $3 million and a market cap of $12.46 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -85.49%.

Overview: <BR>Allarity Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 12.46 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.41 <BR>Return on Equity: -85.49% <BR>Price to Book: 0.67<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Allarity Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Allarity Therapeutics, Inc. shows a mildly bullish trend with mixed technical indicators, having underperformed the S&P 500 recently but significantly outperformed it over the past month.

As of 8 September 2025, the technical trend for Allarity Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a mildly bullish stance, while the monthly MACD is also mildly bullish. The RSI shows a bearish signal on the weekly timeframe but is bullish on the monthly. Moving averages are bullish on the daily timeframe, and the KST is bullish weekly but bearish monthly. The Dow Theory suggests a mildly bullish stance on the weekly timeframe with no trend on the monthly. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the past week with a return of -15.05% compared to the S&P's 1.05%, but it has significantly outperformed over the past month with a return of 73.61% versus the S&P's 2.33%. Overall, the current technical stance is mildly bullish, driven by the mixed signals from the MACD, moving averages, and Dow Theory.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 27 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.35

stock-summary
Return on Equity

-118.42%

stock-summary
Price to Book

2.26

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-36.26%
0%
-36.26%
6 Months
31.97%
0%
31.97%
1 Year
9.43%
0%
9.43%
2 Years
-99.67%
0%
-99.67%
3 Years
132.0%
0%
132.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Allarity Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Allarity Therapeutics, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Allarity Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a mildly bullish stance, while the monthly MACD is also mildly bullish. The RSI shows a bearish signal on the weekly timeframe but is bullish on the monthly. Moving averages are bullish on the daily timeframe, and the KST is bullish weekly but bearish monthly. The Dow Theory suggests a mildly bullish stance on the weekly timeframe with no trend on the monthly. In terms of performance, the stock has underperformed the S&P 500 over the past week with a return of -15.05% compared to the S&P's 1.05%, but it has significantly outperformed over the past month with a return of 73.61% versus the S&P's 2.33%. Overall, the current technical stance is mildly bullish, driven by the mixed signals from the MACD, moving averages, and Dow Theory....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
8.75%
EBIT to Interest (avg)
-20.62
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.41
Sales to Capital Employed (avg)
0
Tax Ratio
1.48%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
5.05%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.68
EV to EBIT
0.83
EV to EBITDA
0.83
EV to Capital Employed
1.77
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
212.90%
ROE (Latest)
-85.49%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (1.14%)

Foreign Institutions

Held by 3 Foreign Institutions (1.18%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -43.75% vs 33.33% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.10",
          "val2": "-3.40",
          "chgp": "-20.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "2.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.30",
          "val2": "-1.60",
          "chgp": "-43.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -105.88% vs 26.09% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.30",
          "val2": "-17.90",
          "chgp": "-2.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.50",
          "chgp": "40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7.00",
          "val2": "5.70",
          "chgp": "-222.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.50",
          "val2": "-11.90",
          "chgp": "-105.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.10
-3.40
-20.59%
Interest
0.00
0.40
-100.00%
Exceptional Items
0.00
2.20
-100.00%
Consolidate Net Profit
-2.30
-1.60
-43.75%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -43.75% vs 33.33% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-18.30
-17.90
-2.23%
Interest
0.70
0.50
40.00%
Exceptional Items
-7.00
5.70
-222.81%
Consolidate Net Profit
-24.50
-11.90
-105.88%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -105.88% vs 26.09% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Allarity Therapeutics, Inc. stock-summary
stock-summary
Allarity Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."